title: Treatment with a gonadotropin-releasing-hormone analog and attainment of full height potential in a male monozygotic twin with gonadotropin-releasing hormone-dependent precocious puberty.
abstract: We report on a pair of male monozygotic twins, one unaffected and the other affected with gonadotropin-releasing hormone (GnRH)-dependent precocious puberty, and discuss the role of treatment with a GnRH analog in the attainment of full height potential in GnRH-dependent precocious puberty. At 1.6 years of age, the affected twin was studied for tall stature (+3.8 SD), and was diagnosed as having GnRH-dependent precocious puberty due to a hypothalamic hamartoma of the tuber cinereum. He was treated with oral cyproterone acetate (110-170 mg/m(2) daily) from 1.8 through 5. 0 years of age, with oral cyproterone acetate and intranasal buserelin acetate (700-900 microg/m(2) daily) from 5.0 through 7.5 years, and with intranasal buserelin acetate alone (1100- 1400 microg/m(2) daily) from 7.5 through 12.6 years. He attained a final height of 171.0 cm at 14.9 years of age (+0.10 SD) and his twin 170. 0 cm at 15.3 years of age (-0.10 SD), with their target height being 174.5 +/- 9.0 cm.
  
  
  CONCLUSIONS
  This study indicates that GnRH analog treatment may preserve near full height potential in some patients with GnRH-dependent precocious puberty.
authors.affiliation: Department of Pediatrics, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 60-8582, Japan. t-ishii@med.keio.ac.jp
authors.forename: T
authors.initials: T
authors.lastname: Ishii
authors.forename: S
authors.initials: S
authors.lastname: Sato
authors.forename: M
authors.initials: M
authors.lastname: Anzo
authors.forename: G
authors.initials: G
authors.lastname: Sasaki
authors.forename: T
authors.initials: T
authors.lastname: Hasegawa
authors.forename: S
authors.initials: S
authors.lastname: Tamai
authors.forename: N
authors.initials: N
authors.lastname: Matsuo
mesh_terms: D000280:Administration, Inhalation; D000284:Administration, Oral; D001827:Body Height / Q000187:drug effects; D002064:Buserelin / Q000008:administration & dosage*; D002675:Child, Preschool; D017373:Cyproterone Acetate / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D007987:Gonadotropin-Releasing Hormone / Q000096:biosynthesis; D006130:Growth Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D006222:Hamartoma / Q000150:complications / Q000175:diagnosis; D006801:Humans; D007027:Hypothalamic Diseases / Q000150:complications / Q000175:diagnosis; D008279:Magnetic Resonance Imaging; D008297:Male; D045167:Progesterone Congeners / Q000008:administration & dosage*; D011629:Puberty, Precocious / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D016896:Treatment Outcome; D014430:Twins, Monozygotic
chemical_list: D045167:Progesterone Congeners; D007987:Gonadotropin-Releasing Hormone; D017373:Cyproterone Acetate; D002064:Buserelin